DDR1: a potential target for triple-negative breast cancer?

Researchers have isolated a key molecule, termed discoidin domain receptor 1 (DDR1), which blocks immune cells from entering breast tumors and destroying the cells inside in triple negative breast cancer (TNBC). Identification of DDR1 could open doors for new treatments of this aggressive form of breast cancer. Triple negative breast cancer accounts for 15% of breast cancer cases. This form of cancer is especially hard to treat because it lacks the receptors commonly targeted by immunotherapy and other cancer therapies. This exclusion of immune cells from tumors is associated with poor outcomes for patients with TNBC. However, a study published by...